Published 6 days ago • loading... • Updated 6 days ago

Real-world data show Cook’s Zilver PTX leads to lower rates of in-stent occlusion than Boston Scientific’s Eluvia - Interventional News

Summary by Interventional News

Zilver PTX Cook Medical has announced that its Zilver PTX drug-eluting stent (DES) has lower rates of in-stent occlusions among patients with restenosis at three years than the Eluvia DES (Boston Scientific), according to real-world data from the REALDES study. The company notes that the data, published by Tsuyoshi Shibata (Sapporo Medical University Hospital, Sapporo, Japan) et al in the European Journal of Vascular and Endovascular Surgery (EJ…

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All

Left

Center

Right

Endovascular Today

REALDES Study Compares Zilver PTX and Eluvia Drug-Eluting Stents at 3 Years - Endovascular Today

March 27, 2025—Investigators seeking to compare real-world outcomes with drug-eluting stents (DES) in symptomatic femoropopliteal lesions have shared results from REALDES, a prospective multicenter observational study. Published in European Journal of Vascular & Endovascular Surgery, Shibata et al enrolled 200 limbs treated with either the Zilver PTX (Cook Medical) or Eluvia (Boston Scientific Corporation) DES and followed them out to 3 years. T…

6 days ago

Read Full Article